Company also announces participation in BioJapan 2019, one of Asia’s largest partnering events for the global biotechnology industry, October 9-11, 2019 in Pacifico Yokohama

LAUPHEIM,GERMANY AND MILFORD, MA, USA - EQS Newswire - October 4, 2019 - Rentschler Biopharma SE, a world-class contract development andmanufacturing organization (CDMO) for biopharmaceuticals, today reportedthat it will further enhance and develop the existing collaboration in Japan withSummit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiaryof Sumitomo Corporation. Through strong collaboration with SPI, RentschlerBiopharma has secured new contracts with Japanese pharmaceutical companies. SPIand Rentschler Biopharma are working together with Japanese clients to outlineprojects from early clinical stage up to commercial launch and ensure optimalservice. Japan is one of the largest biopharmaceutical marketsin the world and is an important area of growth for Rentschler Biopharma.

Dr. Frank Mathias, CEO of Rentschler Biopharma,noted: "Our relationship with SPI has been highly productive and fruitful andwe have been impressed by their strong network and extensive experience incontract manufacturing and supply. Japanese pharmaceutical companies are playingan important and expanding role in the global healthcare market, and we aredelighted to be continuing this productive collaboration as we grow our clientbase in Japan."

Federico Pollano, Senior Vice PresidentBusiness Development of Rentschler Biopharma, added: "We are pleased to beexpanding our business with Japanese pharmaceutical companies who valueRentschler Biopharma for our excellent services, outstanding quality andextensive track-record. We very much look forward to working together with SPI toprovide clients with the best possible advice and assistance from the start ofclinical trials to commercial launch."

Rentschler Biopharma also announced itspresence at BioJapan 2019, which is being held October9-11, 2019 in Pacifico Yokohama. The Company is a bronze sponsor of thisimportant partnering event. Federico Pollano willgive a presentation, titled "Tailormade one-stop-shop solutions fordevelopment and production of biopharmaceuticals", on Wednesday, October 9,11:30-12:00 at the Exhibitor's Stage. Dr. Frank Mathias, Federico Pollano andhis Business Development team, which includes SPI, will be available to meet atRentschler Biopharma's booth (#D-48).

Japanis the world's third largest pharmaceuticals market, which is forecast to reach$89 to $93 billion by 2023. The country is expected to continue dominating thiscorner of the global market[i]. Thereare over 100 domestic pharmaceutical companies in Japan, with many of themid-sized and larger-sized firms in recent years developing drug candidateswith innovative and new modalities, such as biologics and gene and celltherapies, for markets worldwide. This is increasing the involvement ofJapanese pharmaceutical companies in biopharmaceutical enterprises. Japan hasalso seen an increase in biopharmaceutical start-ups, which is further drivingthe industry's growth.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract developmentand manufacturing organization (CDMO), focused exclusively onclient projects. From its headquarters in Laupheim, Germany, and its site inMilford, MA, USA, Rentschler Biopharma offers process development and manufacturingof biopharmaceuticals as well as related consulting activities, includingproject management and regulatory support. Rentschler Biopharma's high qualityis proven by its long-standing experience and excellence as a solution partnerfor its clients. A high-level quality management system, a well-establishedoperational excellence philosophy and advanced technologies ensure productquality and productivity at each development and manufacturing step. In orderto offer optimal solutions across the entire value chain, the Company hasentered into a strategic alliance with Leukocare AG for formulation developmentand with Rentschler Fill Solutions GmbH for fill & finish services. RentschlerBiopharma is a family-owned company with more than 850 employees. For furtherinformation, please visit www.rentschler-biopharma.com.